Eli Lilly and Company completes $1.4bn acquisition of POINT Biopharma
Eli Lilly and Company (NYSE: LLY) has announced the successful completion of its $1.4 billion acquisition of POINT Biopharma Global Inc. (NASDAQ: PNT), a notable ... Read More
Windjammer Capital acquires monoclonal antibodies producer Bio X Cell
Windjammer Capital Investors ("Windjammer"), a notable private equity investment firm, has announced its acquisition of Bio X Cell, LLC ("BXC"), marking a significant move in ... Read More
AstraZeneca to acquire Icosavax in $1.1bn deal to boost vaccine development
In a definitive move, AstraZeneca has entered into an agreement to acquire Icosavax, Inc., a U.S.-based biopharmaceutical company specializing in innovative vaccines. This acquisition, valued ... Read More
Sun Pharmaceutical proposes revised offer for Taro Pharmaceutical acquisition
In a notable development within the pharmaceutical industry, Sun Pharmaceutical Industries Limited has expressed a non-binding interest in acquiring shares of Taro Pharmaceutical Industries Ltd. ... Read More
AbbVie to acquire Cerevel Therapeutics for $8.7bn to expand neuroscience research
AbbVie Inc. (NYSE: ABBV) and Cerevel Therapeutics (NASDAQ: CERE) have announced a definitive agreement in which AbbVie will acquire Cerevel Therapeutics. The transaction, valued at ... Read More
Roche to acquire Carmot Therapeutics to expand obesity treatment portfolio
Roche announced its definitive agreement to acquire Carmot Therapeutics, Inc., based in Berkeley, California, for an upfront purchase price of USD 2.7 billion, with additional ... Read More
AbbVie to acquire ImmunoGen for $10.1bn to expand oncology portfolio
AbbVie Inc. and ImmunoGen Inc. have entered into a definitive agreement, marking a significant move in the pharmaceutical industry. AbbVie will acquire ImmunoGen, including its ... Read More
Boehringer Ingelheim expands oncology portfolio with T3 Pharma acquisition
Boehringer Ingelheim announced its acquisition of T3 Pharmaceuticals AG (“T3 Pharma”), a Swiss biotech company specializing in immuno-oncology, for up to 450 million CHF. T3 ... Read More
Merck to acquire Caraway Therapeutics in $610m deal for neurodegenerative disease treatments
Merck and Caraway Therapeutics, Inc. have announced a definitive agreement in which Merck, through a subsidiary, will acquire Caraway Therapeutics. The total potential consideration for ... Read More
Roche announces $7.1bn deal to acquire Telavant and RVT-3101 antibody
Switzerland-based Roche has officially declared its acquisition agreement for Telavant Holdings, Inc., a Roivant company collaboratively owned by Roivant Sciences Ltd. and Pfizer Inc. The ... Read More